Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Proliferative Diabetic Retinopathy
Interventions: Macugen, Sham; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age-Related Macular Degeneration
Interventions: Streetlab VR; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions: Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT); Procedure · Drug
Lead sponsor: RETINA-AI Health, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Retinopathy of Prematurity (ROP)
Interventions: myo-Inositol 5% Injection, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Cystoid Macular Edema
Interventions: Standard Care, nepafenac; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age-Related Macular Degeneration, Cataract
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years to 100 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Low Vision
Interventions: Eye4, Placebo; Device · Other
Lead sponsor: Eyedaptic; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Retinopathy of Prematurity
Interventions: Goggles, Ambient Light Reduction; Device · Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Up to 1 Day
Timeline: Started 1995
U.S. locations: 3
States / cities: Buffalo, New York • Dallas, Texas • San Antonio, Texas

Conditions: Diabetes, Diabetic Retinopathy
Interventions: DVS supplementation; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Pomona, California • Tahlequah, Oklahoma

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: Goji berry, Fiber; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 65 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Beverly Hills, California • Los Angeles, California • Mountain View, California + 9 more

Conditions: Leber Congenital Amaurosis
Interventions: AAV RPE65; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Months to 115 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1994
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions: multi-component nutritional supplement capsules, multi-component dietary supplement; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Interventions: K8; Drug
Lead sponsor: Inflammasome Therapeutics; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Loma Linda, California • Lexington, Kentucky • Portland, Maine + 6 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Globulin, Immune, Ganciclovir; Drug
Lead sponsor: American National Red Cross; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cardiovascular Risk
Interventions: CLAiR Artificial Intelligence Software; Device
Lead sponsor: Toku Eyes Ltd; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Homer Glen, Illinois • Canton, Ohio

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Complement Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Mountain View, California • Oak Forest, Illinois • Springfield, Illinois + 7 more

Conditions: Geographic Atrophy
Interventions: Lampalizumab, Sham Comparator; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 6 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Dallas, Texas

Conditions: Posterior Vitreous Detachment, Diabetic Retinopathy
Interventions: annular array ultrasound exam; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Interventions: Prescreening Assessments; Diagnostic Test
Lead sponsor: Ascidian Therapeutics, Inc; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more

Search by objective public record fields.

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

Inositol to Reduce Retinopathy of Prematurity

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Age-Related Eye Disease Study (AREDS) Follow-Up

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

ACCESS: AI for pediatriC diabetiC Eye examS Study

Effects of Goji vs. Fiber on Macular Degeneration

Seven Year Update of Macular Degeneration Patients

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Diabetes Visual Function Supplement Study

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

Precision Study of CLAiR AI Software

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Annular Array Ultrasound in Ophthalmology

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)